Correlation of low expression of hMOF with clinicopathological features of colorectal carcinoma, gastric cancer and renal cell carcinoma

Cao,Lingling; Zhu,Lin; Yang,Jiaxing; Su,Jiaming; Ni,Jinsong; Du,Yujun; Liu,Da; Wang,Yanfang; Wang,Fei; Jin,Jingji; Cai,Yong

doi:10.3892/ijo.2014.2266

Correlation of low expression of hMOF with clinicopathological features of colorectal carcinoma, gastric cancer and renal cell carcinoma

Authors:
- Lingling Cao
- Lin Zhu
- Jiaxing Yang
- Jiaming Su
- Jinsong Ni
- Yujun Du
- Da Liu
- Yanfang Wang
- Fei Wang
- Jingji Jin
- Yong Cai
View Affiliations

Affiliations: School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China, Department of Gastrointestinal Surgery, The First Clinical Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Pathology, The First Clinical Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Nephrology, The First Clinical Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: January 21, 2014 https://doi.org/10.3892/ijo.2014.2266
Pages: 1207-1214

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human MOF (males absent on the first), as a histone acetyltransferase, is responsible for histone H4K16 acetylation in human cells. Recent studies have shown that the abnormal gene expression of hMOF is involved in certain primary cancers. Here, we first report the involvement of hMOF expression in clinically diagnosed primary colorectal carcinoma (CRC) and gastric cancer. Simultaneously, the correlation of hMOF expression and clinicopathological features in CRC, gastric cancer and renal cell carcinoma (RCC) was analyzed. The hMOF mRNA expression was assessed in 44 CRC, 16 gastric cancer and 47 RCC human tissue samples by quantitative PCR (qPCR). Statistical analysis of qPCR data revealed a significant reduction (>2-fold decrease) of hMOF gene expression in CRC, 57% (25/44), 94% (15/16) in gastric cancer and 74% (35/47) in RCC tissues of the patients. In patients with CRC, lymph node metastasis and tumor stage were associated with hMOF expression patterns. However, no significant association between hMOF expression and tumor types emerged (p>0.05). Interestingly, in patients with gastric cancer, although no statistically significant difference was found between adjacent (<2 cm away from the cancer tissue) and normal tissues (>5 cm away from the cancer tissue), >2-fold reduction of hMOF expression in adjacent tissues had already appeared in 35% of patients. In addition, low expression of hMOF was strongly correlated with tumor differentiation (p<0.05) and survival of patients with gastric cancer (p<0.001). While in patients with RCC, downregulation of hMOF was connected to ccRCC and tissues with T1 tumor status. Our results suggest that downregulation of hMOF may be common in cancer tissues, and may represent a novel biomarker for tumor diagnosis.

View Figures

View References

1.	Jin J, Cai Y, Li B, Conaway RC, Workman JL, Conaway JW and Kusch T: In and out: histone variant exchange in chromatin. Trends Biochem Sci. 30:680–687. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Waldmann T and Schneider R: Targeting histone modifications - epigenetics in cancer. Curr Opin Cell Biol. 25:184–189. 2013. View Article : Google Scholar : PubMed/NCBI
3.	Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar
4.	Bannister AJ and Kouzarides T: Regulation of chromatin by histone modifications. Cell Res. 21:381–395. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Hatzimichael E and Crook T: Cancer epigenetics: new therapies and new challenges. J Drug Deliv. 2013:5293122013. View Article : Google Scholar : PubMed/NCBI
6.	Haberland M, Montgomery RL and Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 10:32–42. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Shi Y: Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet. 8:829–833. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Feinberg AP, Ohlsson R and Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet. 7:21–33. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Jones PA and Martienssen R: A blueprint for a human epigenome project: the AACR human epigenome workshop. Cancer Res. 65:11241–11246. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Fraga MF, Ballestar E, Villar-Garea A, et al: Loss of acetylation at Lys 16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 37:391–400. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Elsheikh SE, Green AR, Rakha EA, et al: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 69:3802–3809. 2009. View Article : Google Scholar
12.	Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al: Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol. 25:4358–4364. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Mosashvilli D, Kahl P, Mertens C, et al: Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 101:2664–2669. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Sharma GG, So S, Gupta A, et al: MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol. 30:3582–3595. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Carrozza MJ, Utley RT, Workman JL and Côté J: The divers functions of histone acetyltransferase complexes. Trends Genet. 19:321–329. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Gupta A, Guerin-Peyrou TG, Sharma GG, et al: The mammalian ortholog of Drosophla MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol Cell Biol. 28:397–409. 2008.
17.	Smith ER, Cayrou C, Huang R, Lane WS, Côté J and Lucchesi JC: A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol. 25:9175–9188. 2005.PubMed/NCBI
18.	Cai Y, Jin J, Swanson SK, et al: Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex. J Biol Chem. 285:4268–4272. 2010. View Article : Google Scholar
19.	Mendjan S, Taipale M, Kind J, et al: Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mol Cell. 21:811–823. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Pfister S, Rea S, Taipale M, et al: The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer. 122:1207–1213. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Wang Y, Zhang R, Wu D, Lu Z, Sun W, Cai Y, Wang C and Jin J: Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma. J Exp Clin Cancer Res. 32:82013. View Article : Google Scholar : PubMed/NCBI
22.	Song JS, Chun SM, Lee JY, Kim DK, Kim YH and Jang SJ: The histone acetyltransferase hMOF is overexpressed in non-small cell lung carcinoma. Korean J Pathol. 45:386–396. 2011. View Article : Google Scholar
23.	Zhao L, Wang DL, Liu Y, Chen S and Sun FL: Histone acetyltransferase hMOF promotes S phase entry and tumorigenesis in lung cancer. Cell Signal. 25:1689–1698. 2013. View Article : Google Scholar : PubMed/NCBI
24.	Sameer AS: Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 3:1142013. View Article : Google Scholar : PubMed/NCBI
25.	Jemal A, Siegel E, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin. 57:43–66. 2007.
26.	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
27.	Tamagawa H, Oshima T, Shiozawa M, et al: The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep. 27:637–642. 2012.PubMed/NCBI
28.	Tamagawa H, Oshima T, Numata M, et al: Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. EJSO. 39:655–661. 2013. View Article : Google Scholar : PubMed/NCBI
29.	Liu N, Zhang R, Zhao X, et al: A potential diagnostic marker for ovarian cancer: involvement of the histone acetyltransferase, human males absent on the first. Oncol Lett. 6:393–400. 2013.
30.	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer; Chicago, IL: 2010
31.	Choschzick M, Oosterwijl R, Muller V, Woelber L, Simon R, Moch H and Tennstedt P: Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch. 459:193–200. 2011. View Article : Google Scholar : PubMed/NCBI
32.	Liu X, Cao L, Ni J, et al: Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues. Int J Oncol. 43:1925–1934. 2013.PubMed/NCBI
33.	Rea S, Xouri G and Akhtar A: Males absent on the first (MOF): from flies to humans. Oncogene. 26:5385–5394. 2007. View Article : Google Scholar : PubMed/NCBI
34.	Taiple M, Rea S, Richter K, Vilar A, Lichter P, Imhof A and Akhtar A: hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol. 25:6798–6810. 2005. View Article : Google Scholar : PubMed/NCBI